

## **GENSIGHT BIOLOGICS**

A French *Société Anonyme* (corporation)

with share capital of 488,511.33 Euros

74 rue du Faubourg Saint Antoine  
75012 Paris  
751 164 757 - Paris Trade and Companies Registry

### **NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF MAY 31, 2017**

#### **USAL NAME :**

Simone SEITER

#### **OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES :**

**Simone Seiter, M.D., Ph.D.**, is Vice President with QuintilesIMS based in Frankfurt, Germany for 10 years. She supports biotech companies, midsize and Top 10 pharma companies in developing commercialization strategies and launching new products. Prior to joining QuintilesIMS Simone Seiter worked at Capgemini as a consultant for six years and served as a postdoctoral Fellow at the National Institute of Health (United States) for two years. Dr. Seiter worked at the Universities of Heidelberg and Homburg, Germany as board certified dermatologist. Dr. Seiter holds an M.D. PhD degree from the University of Heidelberg and an MBA degree from the University of Applied Sciences in Neu-Ulm, Germany.

#### **OFFICES IN THE COMPANY**

None

#### **NUMBER OF SHARES OF THE CORPORATION OWNED :**

0

## **GENSIGHT BIOLOGICS**

A French *Société Anonyme* (corporation)

with share capital of 488,511.33 Euros

74 rue du Faubourg Saint Antoine  
75012 Paris  
751 164 757 - Paris Trade and Companies Registry

### **NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF MAY 31, 2017**

#### **USAL NAME :**

Natalie MOUNT

#### **OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES :**

**Natalie Mount, Ph.D.**, is Chief Scientific Officer with GammaDelta since 2017. Prior to this, she spent four years at the Cell and Gene Therapy Catapult where she was Chief Clinical Officer, having been recruited to build the Catapult from the startup phase. At the Catapult, Natalie Mount was responsible for the translational, regulatory and clinical development activities across the broad portfolio including immune therapies and stem cell based programs. She also acted as an advisor to academics and small companies developing cell based therapies. Natalie Mount's prior experience also includes 16 years at Pfizer, leading development activities across various therapeutic areas, including cell based therapies in the Regenerative Medicine Unit. Dr. Mount has a first class degree in Natural Sciences from the University of Cambridge and a PhD from University College, London.

#### **OFFICES IN THE COMPANY :**

None

#### **NUMBER OF SHARES OF THE CORPORATION OWNED :**

0

## **GENSIGHT BIOLOGICS**

A French *Société Anonyme* (corporation)

with share capital of 488,511.33 Euros

74 rue du Faubourg Saint Antoine  
75012 Paris  
751 164 757 - Paris Trade and Companies Registry

### **NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF MAY 31, 2017**

#### **USAL NAME :**

Peter GOODFELLOW

#### **OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES :**

**Peter Goodfellow, Ph.D.**, is a science advisor and consultant for Abingworth, Sanofi and the Bill and Melinda Gates Foundation. Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GSK) as head of research. He has founded several biotechnology companies and has sat on the Boards of Prosensa Holdings N.V., deCode and several medical charities. Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.

#### **OFFICES IN THE COMPANY :**

Administrator

#### **NUMBER OF SHARES OF THE CORPORATION OWNED :**

47, 000 share subscription warrants (*BSA - Bons de Souscription d'Actions*)